-
OBN Launch BioForward® Conference
The ‘Roadmap for Growth’ Life Sciences Event Oxford, UK, 19th February 2018 / Sciad Newswire / OBN (UK) Ltd, the membership organisation supporting the life sciences industry, is delighted to announce the launch of BioForward, a unique, high-quality, international conference, focussed on creating and developing a practical roadmap for early stage, emerging, and developing companies to achieve…
-
Investment and Innovation – key insights from this year’s Biotech and Money World Congress
This year’s Biotech and Money / Medtech and Money World Congress brought together biotech companies and investors from across the world for the 4th annual event. As well as pitches and workshops, the event hosted a number of interesting discussions about the current state of the biotech sector. AI was a hot topic at both…
-
Naviswiss Hip Navigation receives CE Approval and CHF 3.5 million Private Equity
Brugg AG, Switzerland, 8th February 2018 / Sciad Newswire / Naviswiss, an independent medical technology company specialized in miniaturized surgical navigation, is glad to announce that it has received the European CE mark for its navigated hip replacement. Miniaturized navigation now becomes available to surgeons in Europe. Furthermore, Naviswiss has successfully closed its financial round D and secured CHF 3.5…
-
LBIC’s Latest Newsletter: featuring Domainex, media liaison advice from Sciad’s own Maria Patey, and more
Sciad Communications has recently been involved with the production of “LBIC news”, the London Bioscience Innovation Centre’s bi-annual newsletter. The newsletter features LBIC’s latest updates, alongside news and insights on companies active in the Biosciences sector. The recent Winter 2017 edition mentions Domainex’s collaboration with Auspherix, the aim of which is to develop new drugs…
-
Positive results achieved in ReViral’s Phase IIa RSV challenge study
ReViral’s RV521 fusion inhibitor produces highly significant reduction in viral load and clinical symptoms London, UK, 5th February 2018 / Sciad Newswire / ReViral, a UK-based biotech company focused on developing novel compounds targeting respiratory syncytial virus (RSV), today announced successful results from its Phase IIa placebo-controlled challenge trial in healthy adult subjects infected intranasally with respiratory syncytial virus…
-
Domainex appoints Dr Kevin Doyle as Head of Chemistry
Cambridge, UK, 1st February 2018 / Sciad Newswire / Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Dr Kevin Doyle has been appointed Head of Chemistry with immediate effect. His appointment strengthens the expanding team of international scientists at its research facilities on Chesterford Research Park, based in Cambridge, UK, which has grown by…
-
Genomics set to transform UK healthcare in 2018, says MedCity
London, UK, 31st January 2018 / Sciad Newswire / 2018 will be a transformative year for UK healthcare as pioneering genomics companies identify people’s risk of disease and deliver more precise treatments, according to Sarah Haywood, CEO of MedCity. Speaking at the Festival of Genomics in London today, the CEO of the life sciences cluster organisation will say that more efficient…
-
Sciad welcomes Juliette Craggs to the team
Whilst studying for my degree I undertook a placement year at GSK working in drug discovery. I was able to witness first-hand the amazing research going on behind the scenes right around the time that the pharmaceutical industry was experiencing huge amounts of negative press coverage. New drugs and treatments were overshadowed by the public…
-
Selcia Joins Eurofins Group
Ongar, UK, 25th January 2018 / Sciad Newswire / Selcia Limited, a leading global provider of custom radiolabelling and integrated drug discovery services, announces that it has been acquired by Eurofins Scientific (EUFI.PA), a global leader in analytical testing and pharma discovery services. The acquisition of Selcia provides Eurofins with an entry into the custom radiolabelling and innovative pre-clinical, integrated…
-
Synpromics Announces New Partnership with UCL to Develop Novel Gene Therapies for Blood-based Disorders
Edinburgh, UK, 25th January 2018 / Sciad Newswire / Synpromics Ltd, the leader in gene control, announces a collaboration with UCL Great Ormond Street Institute of Child Health, to develop novel gene therapies for pathologies affecting the haematopoietic system. This new partnership further expands Synpromics’ activities in the cell and gene therapy sector, as it builds on its strategy…